相关实验视频
Updated: Sep 10, 2025

07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
33.5K
IDOR-1104-0086,一种具有抗作用的新型Kv7通道激活剂
Melanie Kessler1, Andreas Mühlemann1, Malgorzata Anna Mis1
1Idorsia Pharmaceuticals Ltd, Department of Drug Discovery, CNS-Pharmacology Division, Allschwil, Switzerland.
Neuropharmacology
|August 27, 2025
概括
一种新的候选药物IDOR-1104-0086通过激活Kv7通道有效地减少焦点发作和普遍发作. 这种有前途的抗发作药物显示出比 retigabine 的效果更大,在临床前模型中耐受性很好.
科学领域:
- 神经科学
- 药理学
- 分子生物学
背景情况:
- 电压通道 (Kv7) 对于调节神经元刺激能力至关重要.
- 激活Kv7通道是一种治疗的策略.
- 现有的Kv7通道开放剂如雷蒂加具有局限性.
研究的目的:
- 描述新型小分子IDOR-1104-0086的抗发作能力.
- 在Kv7异型中比较其强度和选择性.
- 评估其在各种动物发作模型中的有效性.
主要方法:
- 在体外表型查中发现IDOR-1104- 0086.
- 目标解卷显示KV7通道激活为其机制.
- 在体内研究中使用了杏仁核激发,6 Hz,最大电击值和缺席式的模型.
- 电生理学 (全细胞补丁) 评估了通道活动.
主要成果:
- 在特定于大脑的Kv7. 2/ 3和Kv7. 3/ 5通道上,IDOR-1104- 0086的效果比雷蒂加宾更强.
- 它在心脏Kv7.1通道上不活跃,这表明外围安全性.
- 该化合物剂量依赖,减少了焦点发作和普遍发作,但加剧了缺席性发作.
- 在体内有效度转移Kv7. 2/ 3电流激活,与其机制一致.
结论:
- IDOR-1104- 0086是一种具有抗发作功能的强效Kv7. 2/ 3通道激活剂.
- 在临床前模型中有效减少焦点发作和普遍发作.
- 这种化合物代表了治疗特定类型的,特别是耐药性的有希望的候选药物.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
445
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
445
Antiepileptic Drugs: Sodium Channel Blockers
869
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
869
Antiepileptic Drugs: GABAergic Pathway Potentiators
635
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
635
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers
608
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
608

